Loading
A phase 1/2 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC is a phase 1/2 interventional study registered as NCT07206498 by Wayshine Biopharm, Inc., with 48 participants planned, started 2025-10-17 and due to reach its primary completion in 2028-10-14. Interventions recorded: Osimertinib (Tagrisso®), WSD0922-FU. Conditions listed: Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Wayshine Biopharm, Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/